NCT07033481进行中（未招募）2 期
A Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Primary Progressive Aphasia (PPA)
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 20
- 试验地点
- 7
- 主要终点
- Incidence of Adverse Events and Serious Adverse Events.
研究概览
简要总结
The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 40 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Men and women aged 40-85 years at Screening.
- •Participant or participant's legally authorized representative (where applicable) is willing and able to provide written informed consent.
- •Clinical diagnosis of nfvPPA by consensus criteria [Gorno-Tempini et al, 2011].
- •At least one of the following core features must be present:
- •Agrammatism in language production
- •Effortful, halting speech with inconsistent speech sound errors and distortions (apraxia of speech)
- •At least 2 of 3 of the following other features must be present:
- •Impaired comprehension of syntactically complex sentences
- •Spared single-word comprehension
- •Spared object knowledge
- •Global CDR® plus National Alzheimer's Coordinating Center Frontotemporal Lobar Degeneration (NACC FTLD) score of 0.5 or 1 during Screening.
- •CDR® plus NACC FTLD language domain score of 0.5, 1 or 2 during Screening.
- •Normal or corrected eyesight and auditory abilities, sufficient to perform all aspects of the study scales and assessments.
- •Fluent in English, per Investigator judgement.
- •Must have reliable study partner that is able to attend all study visits with participant. Study partner must be able to read, write, and understand the English language.
排除标准
- •Brain Magnetic Resonance Image (MRI) incompatible with a diagnosis of nfvPPA.
- •History or evidence of a central nervous system (CNS) condition other than nfvPPA which may cause symptoms of aphasia or dementia, including but not limited to Alzheimer's disease (AD), Dementia with Lewy Bodies (DLB), inflammatory/demyelinating CNS conditions, Creutzfeldt Jakob disease, vascular dementia, post-stroke dementia, etc.
- •Features or Parkinsonism, corticobasal syndrome or progressive supranuclear palsy that are as or more prominent than the language features of nfvPPA, and/or motor features which are sufficiently severe that they could significantly impact performance on any of the clinical or neuropsychological measures.
- •Plasma pTau217 result with a high likelihood of the presence of amyloid pathology at Screening or documented evidence of positive biomarkers associated with Alzheimer's disease pathology (e.g., abnormal plasma Aβ42/40 ratio, abnormal CSF phospo-tau/amyloid ratio, or presence of amyloid tracer update on brain amyloid positron emission tomography [PET] imaging).
- •Known progranulin (GRN) mutations.
- •Ongoing major and active psychiatric disorder and/or other concurrent medical condition that, in the opinion of the Investigator, might compromise safety and/or compliance with study requirements.
- •Metabolic or toxic encephalopathy or dementia due to a general medical condition.
- •History of previous neurosurgery to the brain within the past five years.
- •Suicidality, defined as active suicidal thoughts within 6 months before Screening or at Baseline, defined as answering yes to items 4 or 5 on the Columbia-Suicide Severity Rating Scale (C-SSRS), or history of suicide attempt in previous 2 years, or, in the Investigator's opinion, at serious risk of suicide.
- •Clinically relevant intellectual impairment that may interfere with the ability to complete the study scales and assessments, at the discretion of the Investigator.
- •Diagnosis of alcohol or drug abuse within the previous 2 years.
- •Poorly controlled clinically significant medical illness, such as hypertension; myocardial infarction within 6 months; uncompensated congestive heart failure or other significant cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or other disease that would interfere with assessment of drug safety.
- •Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 × the upper limit of normal (ULN), total bilirubin >1.5 × ULN, and/or International Normalized Ratio (INR) >1.
- •If participant has a documented history of Gilbert's syndrome, criterion of total bilirubin >1.5 x ULN is not applicable.
- •If participant is taking anticoagulants (e.g., warfarin), and has no known liver issues, INR >
- •Known human immunodeficiency virus, hepatitis B, or active hepatitis C virus infection.
- •Participated in a study of an investigational drug or transcranial direct current stimulation less than 6 weeks or 5 half-lives of an investigational drug, whichever is longer, before enrollment in this study.
- •Male with female partner(s) of childbearing potential, unwilling or unable to adhere to contraception requirements specified in the protocol.
- •Female of childbearing potential (see Section 5.10), with a positive pregnancy test result during Screening and are unwilling or unable to adhere to contraception requirements specified in the protocol.
- •Weight less than 50 kg at Screening.
- •The following additional exclusion criteria applies for participants undergoing (18F-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography) 18F-FDG PET-CT (18F-FDG PET-CT scans are optional):
- •Blood glucose levels >200 mg/dL.
- •Contraindications to having a PET scan.
研究组 & 干预措施
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
Neflamapimod
Experimental
干预措施: Neflamapimod (Drug)
结局指标
主要结局
Incidence of Adverse Events and Serious Adverse Events.
时间窗: Baseline to Week 36
The number and proportion of participants experiencing adverse events (AEs) and serious adverse events (SAEs) during the study period, categorized by severity and relationship to the study intervention.
次要结局
未报告次要终点
研究者
研究点 (7)
Loading locations...
相似试验
进行中（未招募）
1 期
A Phase 2b Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)CTIS2023-504373-20-00Eip Pharma Inc.160
已完成
2 期
Efficacy Study of p38 Kinase Inhibitor to Treat Patients With AtherosclerosisVascular DiseasesNCT00570752Bristol-Myers Squibb72
进行中（未招募）
1 期
An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients with Dementia with Lewy Bodies (DLB)Dementia with Lewy Bodies (DLB)MedDRA version: 20.0Level: PTClassification code: 10067889Term: Dementia with Lewy bodies Class: 100000004852CTIS2024-511446-39-00Eip Pharma Inc.20
尚未招募
2 期
STUDY ON AKKARAM(STOMATITIS)WITH EVALUATION OF SIDDHA DRUGAKKARAM ENNAICTRI/2021/01/030644Government siddha medical college
尚未招募
2 期
Efficacy of Siddha medicine Vaazhaipoo nei (internal) for Akkaram (Apthous Stomatitis)CTRI/2024/06/069062Government Siddha Medical College